Capstone Investment Advisors Netherlands B.V. Acquires Shares of 2,424 Gilead Sciences, Inc. (GILD)
Capstone Investment Advisors Netherlands B.V. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,424 shares of the biopharmaceutical company’s stock, valued at approximately $172,000.
Several other hedge funds have also recently added to or reduced their stakes in GILD. Renaissance Technologies LLC raised its holdings in shares of Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after acquiring an additional 2,700,600 shares in the last quarter. Vanguard Group Inc. raised its holdings in Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. BlackRock Inc. raised its holdings in Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares in the last quarter. Pioneer Investment Management Inc. raised its holdings in Gilead Sciences by 84.0% in the second quarter. Pioneer Investment Management Inc. now owns 3,493,148 shares of the biopharmaceutical company’s stock worth $247,245,000 after purchasing an additional 1,595,085 shares in the last quarter. Finally, Neuberger Berman Group LLC raised its holdings in Gilead Sciences by 90.9% in the second quarter. Neuberger Berman Group LLC now owns 2,583,196 shares of the biopharmaceutical company’s stock worth $182,839,000 after purchasing an additional 1,229,916 shares in the last quarter. Hedge funds and other institutional investors own 76.23% of the company’s stock.
GILD has been the subject of a number of recent research reports. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Deutsche Bank reiterated a “buy” rating and issued a $81.00 target price on shares of Gilead Sciences in a report on Thursday, August 31st. Credit Suisse Group set a $79.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, August 28th. Argus upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a report on Thursday, August 31st. Finally, Berenberg Bank set a $86.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday, August 29th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $85.22.
In related news, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 546,819 shares of company stock worth $41,808,839. 1.30% of the stock is owned by insiders.
Gilead Sciences, Inc. (NASDAQ GILD) opened at $73.29 on Wednesday. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The stock has a market cap of $95,475.20, a PE ratio of 7.63, a PEG ratio of -1.22 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the prior year, the company posted $2.75 earnings per share. The company’s revenue for the quarter was down 13.2% compared to the same quarter last year. sell-side analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.84%. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.69%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.